VSV-EBOVAC brings together 12 leading international, both clinical and high tech, vaccine research institutes from 6 EU countries and USA as well as two African clinical sites. The partners provide state-of-the art facilities and clinical vaccination research infrastructures that will work together to facilitate Ebola vaccine development.

The VSV-EBOVAC project is coordinated by the Sclavo Vaccines Association (www.sclavo.org), a non-profit organization devoted to support research and development of human vaccines.

VSV-EBOVAC Partners

Sclavo Vaccines Association (IT)
University of Geneva (CH)
BioProtection Systems (US)
Academisch Ziekenhuis Leiden (NL)
University of Gothenburg (SE)
University of Siena (IT)
Emory University (US)
The Chancellor, Masters and Scholars of the University of Oxford (UK)
Eberhard Karls Universitaet Tuebingen (DE)
MICROBIOTEC srl (IT)
Spiez Laboratory, Federal Office for Civil Protection (CH)
Department of Health, Medicines and Healthcare Products Regulatory Agency -National Institute for Biological Standards and Control (UK)

Third Parties:

KEMRI/Wellcome Trust Laboratories (KE)
Centre de Recherches Médicales de Lambaréné (GA)